T-Cell Lymphoma Market

T-Cell Lymphoma Market by Types (Peripheral T-cell Lymphoma and Cutaneous T-cell lymphoma), Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell therapy, and Other types of therapy), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1294
  • Author: Growth Market Reports
  • Rating: 4.7
  • Total Reviews: 3
  • No. Of Pages: 184
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global T-cell Lymphoma market size was valued at USD 4.6 billion in 2020 and is projected to reach USD 20.3 billion by 2028, expanding at a CAGR of 20.2% during the forecast period, 2021–2028. The growth of the market is attributed to the approval of Yescarta, Kymriah, and Tecartus and changing preference of organizations towards adoptive therapies.

T-Cell Lymphoma Market summary

Lymphoma is the most well-known blood disease. It happens when cells of the safe framework, called lymphocytes (a sort of white platelets), develop and increase wildly in the human body. Lymphoma is a kind of blood malignant growth that creates when white platelets called lymphocytes outgrow control. Lymphocytes are important for your safe framework. They travel around your body in your lymphatic framework, assisting you with battling contaminations. There are two kinds of lymphocyte: T lymphocytes (T cells) and B lymphocytes (B cells). Lymphomas can be assembled as Hodgkin lymphomas or non-Hodgkin lymphomas, contingent upon the kinds of cell they contain. Immune system microorganism lymphomas are non-Hodgkin lymphomas that create from T lymphocytes.

Market Trends, Drivers, Restraints, and Opportunities

  • Rising cases of lymphoma malignant growth because of radiations and increase in the quantity of T-cell lymphoma-explicit treatments are expected to boost the market during the forecast period.
  • Rapid growth in the adoption of premium-valued items like keytruda, opdivo, and insusceptible designated spot inhibitors and the launch of a several novel treatments with label expansion of commercialized items are estimated to boost the market during the forecast period.
  • Increasing focus on health treatment is expected to boost the market during the forecast period.
  • High price related with T-cell lymphoma treatment and the adverse symptoms of treatments are projected to hinder the market growth.
  • R&D investment and technological advancement in cancer immunotherapy is projected to create immense opportunities for market players.

Scope of the Report

The report on the global T-cell lymphoma market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Global T-cell lymphoma Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Peripheral T-cell lymphoma(Cutaneous T-Cell lymphoma), and  T-cell lymphoblastic lymphoma) and Therapy (Radiotherapy, Chemotherapy,  Immunotherapy, Stem Cell therapy, and other types of therapy)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Novartis AG, Merck &Co. Inc., F.Hoffmann-La Roche Ltd, Bristol Myers Squibb Company, and Johnson & Johnson(Janssen Pharmaceuticals Inc.)

Market Segment Insights

The cutaneous T-cell lymphoma segment is projected to constitute a major market share

Based on types, the T-cell lymphoma market is bifurcated into peripheral T-cell lymphoma and cutaneous T-cell lymphoblastic lymphoma. The cutaneous T-cell lymphoma (CTCL) segment is expected to hold a key share of the market during the forecast period owing to yearly occurrence of CTCL is 0.4 to 1 case per 100,000 (or 1,000 to 3,000 new cases each year) in the US. Notwithstanding, death pace of CTCL isn't high and patients can live with CTCL around at least 10. The normal assessed commonness of CTCL in the U.S. is around 20,000. Consequently, this makes CTCL most predominant sort of immune system microorganism lymphoma. Adcertis makes PTCL one of the quickest developing T-cell lymphoma type markets.

T-Cell Lymphoma Market types

The chemotherapy segment is expected to grow at a rapid pace

Based on therapy, the T-cell lymphoma market is segregated into chemotherapy, immunotherapy, radiotherapy, stem cell therapy, and other type of therapy. The chemotherapy segment is anticipated to hold major market share of market during the forecast period owing to the most well-known type of therapeutics used to stop the development of malignant cells. Medical procedure and radiation treatment works by eliminating, murdering, or harming the disease cells in a specific region, yet chemotherapy works all through the entire body, favorable reimbursement strategy for therapeutics medications make them accessible and reasonable. For example, Pralatrexate is a chemotherapy drug that is utilized in the treatment of patients with stubborn fringe T-cell lymphoma (PTCL) is recorded under the PBS conspire by the Australian government. Subsequently, with the rising awareness about the advantages of chemotherapy and great government arrangements, the market is projected to boost during the forecast period.

North America is expected to hold a major market share

On the basis of regions, the T-cell lymphoma market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is anticipated to hold major a major market share during the forecast period. Growth of the market is attributed to high prevalence of T-cell lymphoma, presence of key market players, and expanding research and development in the region. The presence of solid research, just as a commercial base combined with a high number of clinical preliminaries being led for T-cell treatments in the U.S., has significantly added to the predominance of the market in the region. Besides, the expanding number of administrative endorsements in the U.S. furthermore, Canada alongside the changing reimbursement strategy in the area has likewise sped up the take-up of these treatments prompting huge market development. However, the market in North America is expected to exhibit a rapid growth in the coming years due to the presence of a considerable number of clinical focuses offering CAR-T cell treatments.

T-Cell Lymphoma Market region
 

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. T-Cell Lymphoma Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. T-Cell Lymphoma Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. T-Cell Lymphoma Market - Supply Chain
  4.5. Global T-Cell Lymphoma Market Forecast
     4.5.1. T-Cell Lymphoma Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. T-Cell Lymphoma Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. T-Cell Lymphoma Market Absolute $ Opportunity
5. Global T-Cell Lymphoma Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. T-Cell Lymphoma Market Size and Volume Forecast by Types
     5.3.1. Peripheral T-cells lymphoma (Cutaneous T-cell lymphoma)
     5.3.2. T-cells lymphoblastic lymphoma
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global T-Cell Lymphoma Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. T-Cell Lymphoma Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global T-Cell Lymphoma Demand Share Forecast, 2019-2026
7. North America T-Cell Lymphoma Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America T-Cell Lymphoma Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America T-Cell Lymphoma Market Size and Volume Forecast by Types
     7.4.1. Peripheral T-cells lymphoma (Cutaneous T-cell lymphoma)
     7.4.2. T-cells lymphoblastic lymphoma
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America T-Cell Lymphoma Demand Share Forecast, 2019-2026
8. Latin America T-Cell Lymphoma Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America T-Cell Lymphoma Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America T-Cell Lymphoma Market Size and Volume Forecast by Types
     8.4.1. Peripheral T-cells lymphoma (Cutaneous T-cell lymphoma)
     8.4.2. T-cells lymphoblastic lymphoma
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America T-Cell Lymphoma Demand Share Forecast, 2019-2026
9. Europe T-Cell Lymphoma Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe T-Cell Lymphoma Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe T-Cell Lymphoma Market Size and Volume Forecast by Types
     9.4.1. Peripheral T-cells lymphoma (Cutaneous T-cell lymphoma)
     9.4.2. T-cells lymphoblastic lymphoma
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe T-Cell Lymphoma Demand Share Forecast, 2019-2026
10. Asia Pacific T-Cell Lymphoma Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific T-Cell Lymphoma Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific T-Cell Lymphoma Market Size and Volume Forecast by Types
     10.4.1. Peripheral T-cells lymphoma (Cutaneous T-cell lymphoma)
     10.4.2. T-cells lymphoblastic lymphoma
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific T-Cell Lymphoma Demand Share Forecast, 2019-2026
11. Middle East & Africa T-Cell Lymphoma Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa T-Cell Lymphoma Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa T-Cell Lymphoma Market Size and Volume Forecast by Types
     11.4.1. Peripheral T-cells lymphoma (Cutaneous T-cell lymphoma)
     11.4.2. T-cells lymphoblastic lymphoma
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa T-Cell Lymphoma Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global T-Cell Lymphoma Market: Market Share Analysis
  12.2. T-Cell Lymphoma Distributors and Customers
  12.3. T-Cell Lymphoma Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Novartis AG,
     12.4.2. Merck &Co. Inc.
     12.4.3.  F. Hoffmann-La Roche Ltd
     12.4.4.  Bristol Myers Squibb Company
     12.4.5.  Johnson & Johnson (Janssen Pharmaceuticals Inc.)
Segments Covered in the Report
The global T-cell lymphoma market has been segmented on the basis of
Types
  • Peripheral T-cells lymphoma (Cutaneous T-cell lymphoma)
  • T-cells lymphoblastic lymphoma
Therapy
  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Stem Cell therapy
  • Other types of therapy
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Novartis AG,
  • Merck &Co. Inc.
  •  F. Hoffmann-La Roche Ltd
  •  Bristol Myers Squibb Company
  •  Johnson & Johnson (Janssen Pharmaceuticals Inc.)

Key players competing in the T-cell lymphoma market include Novartis AG, Merck &Co. Inc., F. Hoffmann-La Roche Ltd, Bristol Myers Squibb Company, and Johnson & Johnson (Janssen Pharmaceuticals Inc.)

Some of these players have adopted several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.

T-Cell Lymphoma Market keyplayers

Buy Report